Effects of antileukotriene among asthmatic patients.
To determine the effect of antileukotriene (montelukast) 10 mg once daily for the treatment of mild to moderate asthma. Open label, prospective. Thirty asthmatic patients > or = 18 years of age with baseline FEV1 > 60 per cent and < or = 80 per cent of predicted values and evidence of reversible airway obstruction, as defined by an increase in FEV1 of > or = 20 per cent. Montelukast 10 mg once daily orally for 12 weeks, back up beta-2 agonist inhaler was available. Spirometry was performed during the screening period, and every month after starting antileukotriene. Subjects recorded asthma-related symptoms and use of supplement beta-2 agonists daily on diary cards. Over 12 weeks of treatment, the FEV1 increased 10 per cent, 14 per cent and 19 per cent respectively, compared to the baseline (p < 0.05). The physician and patients evaluation scores were quite good in the study. Oral montelukast once daily gave a favorable effect in management of mild to moderate asthmatic patients.